Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

NCT00622401 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Dendritic Cell/Tumor Fusion Vaccine
DRUG: Interleukin-12
DRUG: Interleukin-12

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]